bosentan anhydrous has been researched along with Diffuse Parenchymal Lung Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belperio, JA; Fishbein, MC; Lynch, JP; Saggar, R | 1 |
| Amoroso, D; Barbano, B; Di Paolo, M; Gigante, A; Palange, P; Romaniello, A; Rosato, E; Tallerini, G | 1 |
| Heresi, GA; Minai, OA | 1 |
| Silver, RM | 1 |
| Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
| Black, CM; Chadha-Boreham, H; Charef, P; Denton, CP; Emery, P; Furst, DE; Guillevin, L; Matucci Cerinic, M; Riemekasten, G; Roux, S; Rubin, LJ; Seibold, JR; Wells, A | 1 |
| Gocho, K; Homma, S; Kusano, E; Ota, H; Sugino, K; Takai, Y | 1 |
| Furuya, Y; Kuwana, M | 1 |
| Nishibu, A; Oyama, N; Sakai, E; Yamamoto, T | 1 |
| Ahmadi-Simab, K; Gross, WL; Hellmich, B | 1 |
| Chapman, JT; Mehta, AC; Minai, OA; Sahoo, D | 1 |
2 review(s) available for bosentan anhydrous and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Bosentan in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2008 |
Endothelin and scleroderma lung disease.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Lung Diseases, Interstitial; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Transforming Growth Factor beta; Treatment Failure | 2008 |
1 trial(s) available for bosentan anhydrous and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Comorbidity; Double-Blind Method; Exercise Test; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Quality of Life; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides; Survival Rate; Young Adult | 2010 |
8 other study(ies) available for bosentan anhydrous and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Pulmonary hypertension complicating connective tissue disease.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Lung Transplantation; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pyridazines; Scleroderma, Systemic; Sulfonamides | 2013 |
Bosentan for digital ulcers prevention does not worsen cardiopulmonary exercise test parameters in SSc patients with interstitial lung disease.
Topics: Adult; Bosentan; Disease Progression; Endothelin Receptor Antagonists; Exercise Test; Female; Fingers; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Receptor, Endothelin A; Respiratory Function Tests; Scleroderma, Systemic; Skin Ulcer; Statistics as Topic; Sulfonamides; Treatment Outcome | 2016 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
[Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cyclophosphamide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2011 |
Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2012 |
Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pulmonary Fibrosis; Scleroderma, Systemic; Sulfonamides; Walking | 2006 |
Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Retrospective Studies; Sulfonamides; Treatment Outcome; Vasodilator Agents; Walking | 2008 |